EU and US could reach trade deal this weekend - Reuters
On Friday, Citi analysts showed a positive stance on Guardant Health (NASDAQ:GH) by raising the price target from $45.00 to $60.00, while reiterating a Buy rating on the company’s shares. The upgrade followed Guardant Health’s report of $201 million in revenue, a figure that aligns with the company’s preliminary announcement of approximately $200 million. According to InvestingPro data, the company has demonstrated impressive momentum with a 109% return over the past year and maintains a GOOD overall financial health score, despite currently trading above its Fair Value.
The reported revenue was bolstered by an increase in clinical volumes, excluding Shield, with approximately 57.3 thousand tests conducted, marking a 24% year-over-year growth. Additionally, biopharma volumes saw a 16% year-over-year increase with around 11 thousand tests. These figures were consistent with Guardant Health’s earlier projections. The company’s strong operational performance is reflected in its robust revenue growth of 31% over the last twelve months, as reported by InvestingPro.
In the fourth quarter, the company’s Precision Oncology revenue reached $184 million, propelled by the growth in volume and the sustained strength of their G360 tests. Guardant Health also shared insights into its Shield product, which contributed approximately $4.1 million in revenue from roughly 6.4 thousand tests.
Looking ahead, Guardant Health has set its FY25 revenue guidance to range between $850 million and $860 million, slightly surpassing the consensus estimate of $846 million. This forecast includes expected Shield revenue of $25 million to $30 million, which is higher than the consensus estimate of around $23.3 million. The company anticipates that both volumes and revenues will be more heavily weighted towards the second half of the year. With a market capitalization of $5.85 billion and a strong current ratio of 4.68, InvestingPro analysis reveals 8 additional key insights about the company’s financial position and growth prospects, available in the comprehensive Pro Research Report.
The guidance further detailed an anticipated cash burn between $225 million and $235 million, along with operating expenses ranging from $815 million to $825 million. In response to these projections and the company’s performance, Citi analysts updated their model and maintained their Buy/High-Risk rating. The increased target price to $60 reflects the analysts’ revised revenue estimates for Guardant Health.
In other recent news, Guardant Health reported fourth-quarter 2024 results that exceeded analyst expectations, with revenue reaching $201.8 million, surpassing the consensus estimate of $186.78 million. This marks a 30% increase year-over-year, driven by a 24% rise in clinical test volume and a 16% increase in biopharma tests. The company’s adjusted earnings per share were -$0.62, beating the expected -$0.78. For the full year 2024, Guardant Health’s total revenue was $739.0 million, a 31% increase from the previous year. Looking ahead, the company raised its 2025 revenue guidance to $850-$860 million, slightly above the analyst consensus, indicating a projected growth of 15-16%. BofA Securities recently increased its price target for Guardant Health to $56, maintaining a Buy rating, as the company’s fiscal year 2025 sales forecast aligns closely with wider financial community estimates. Guardant Health also reported progress with its Shield colorectal cancer screening test, which has been selected for inclusion in the NIH Vanguard multi-cancer detection study. Additionally, the company is managing expenses with operational costs expected to grow by only 8-9% year-over-year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.